Search | Page 11 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Interviews with the Experts: Hemolysis in PNH and Beyond

    ... proteins.  What happens in PNH is that an acquired mutation in a gene ( PIG-A gene ) in hematopoietic stem cells ...

    Interview last updated 08/31/2016 - 8:40am.

  2. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... intermediate-risk MDS settings and a specific genetic mutation (deletion in the long arm of chromosome 5, abbreviated as del(5q). ... longer used to treat MDS due to its side effects. The mutation of del(5q) is important as it likely deletes genes that are important ...

    Research Review last updated 05/02/2016 - 9:12am.

  3. Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation

    ... evaluate 1 dose level of AG-120 in patients with an IDH1 mutation and 2 dose levels of AG-221 in patients with an IDH2 mutation. AG-120 or AG-221 will be administered with 2 types of AML induction ...

    Clinical Trial last updated 04/28/2016 - 4:16pm.

  4. Dr. Vivienne Rebel reviews a recent study about p53 protein levels as a prognostic factor in MDS

    ... have shown that if the 5q deletion is accompanied by a mutation in the p53 gene (the official name of this gene in TP53), there is ... risk was clear even if the number of cells showing this mutation was relatively small.  The method currently used to identify p53 ...

    Research Review last updated 05/02/2016 - 9:17am.

  5. Myelofibrosis (MF)

    ... to myelofibrosis over time The presence of the JAK2 mutation Exposure to certain industrial chemicals, such as toluene and ...

    Topic section last updated 07/07/2016 - 3:16pm.

  6. PNH: Secondary Mutations and Thrombosis

    ... a brief overview of the common PIG-A gene mutation that occurs in PNH patients and how different patients have ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  7. Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

    ... in patients with AML and high risk MDS with FLT3-ITD mutation . The safety of this drug combination will also be studied. ...

    Clinical Trial last updated 04/29/2016 - 12:23pm.

  8. Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation

    ... hematologic malignancies that harbor an IDH1 and/or IDH2 mutation Status:  ...

    Clinical Trial last updated 04/28/2016 - 10:59am.

  9. Clinical mutations associated with MDS and their importance for disease outcome

    ... new drugs based on what we know about a specific mutation in a specific gene. This study analyzed samples from 738 ...   this was 49 months for patients with one oncogenic mutation, 42 for patients with two oncogenic mutations, and 27, 18 and four ...

    Research Review last updated 05/02/2016 - 9:21am.

  10. Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

    ... t(3;3) t(6;9) t(9;22) Normal karyotype with FLT3-ITD mutation Chronic myelogenous leukemia (accelerated, blast or ...

    Clinical Trial last updated 05/09/2016 - 3:58pm.